BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 37816348)

  • 1. MesoGraph: Automatic profiling of mesothelioma subtypes from histological images.
    Eastwood M; Sailem H; Marc ST; Gao X; Offman J; Karteris E; Fernandez AM; Jonigk D; Cookson W; Moffatt M; Popat S; Minhas F; Robertus JL
    Cell Rep Med; 2023 Oct; 4(10):101226. PubMed ID: 37816348
    [TBL] [Abstract][Full Text] [Related]  

  • 2. New Insights on Diagnostic Reproducibility of Biphasic Mesotheliomas: A Multi-Institutional Evaluation by the International Mesothelioma Panel From the MESOPATH Reference Center.
    Galateau Salle F; Le Stang N; Nicholson AG; Pissaloux D; Churg A; Klebe S; Roggli VL; Tazelaar HD; Vignaud JM; Attanoos R; Beasley MB; Begueret H; Capron F; Chirieac L; Copin MC; Dacic S; Danel C; Foulet-Roge A; Gibbs A; Giusiano-Courcambeck S; Hiroshima K; Hofman V; Husain AN; Kerr K; Marchevsky A; Nabeshima K; Picquenot JM; Rouquette I; Sagan C; Sauter JL; Thivolet F; Travis WD; Tsao MS; Weynand B; Damiola F; Scherpereel A; Pairon JC; Lantuejoul S; Rusch V; Girard N
    J Thorac Oncol; 2018 Aug; 13(8):1189-1203. PubMed ID: 29723687
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Malignant Mesothelioma subtyping via sampling driven multiple instance prediction on tissue image and cell morphology data.
    Eastwood M; Marc ST; Gao X; Sailem H; Offman J; Karteris E; Fernandez AM; Jonigk D; Cookson W; Moffatt M; Popat S; Minhas F; Robertus JL
    Artif Intell Med; 2023 Sep; 143():102628. PubMed ID: 37673586
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Deep learning-based classification of mesothelioma improves prediction of patient outcome.
    Courtiol P; Maussion C; Moarii M; Pronier E; Pilcer S; Sefta M; Manceron P; Toldo S; Zaslavskiy M; Le Stang N; Girard N; Elemento O; Nicholson AG; Blay JY; Galateau-Sallé F; Wainrib G; Clozel T
    Nat Med; 2019 Oct; 25(10):1519-1525. PubMed ID: 31591589
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Myxoid variant epithelioid pleural mesothelioma defines a favourable prognosis group: an analysis of 191 patients with pleural malignant mesothelioma.
    Alchami FS; Attanoos RL; Bamber AR
    J Clin Pathol; 2017 Feb; 70(2):179-182. PubMed ID: 27798081
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Interobserver variation in the assessment of the sarcomatoid and transitional components in biphasic mesotheliomas.
    Dacic S; Le Stang N; Husain A; Weynand B; Beasley MB; Butnor K; Chapel D; Gibbs A; Klebe S; Lantuejoul S; Roden AC; Roggli V; Tazelaar H; Vignaud JM; Galateau-Sallé F
    Mod Pathol; 2020 Feb; 33(2):255-262. PubMed ID: 31273316
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of mesothelioma histologic subtype on outcomes in the Surveillance, Epidemiology, and End Results database.
    Meyerhoff RR; Yang CF; Speicher PJ; Gulack BC; Hartwig MG; D'Amico TA; Harpole DH; Berry MF
    J Surg Res; 2015 Jun; 196(1):23-32. PubMed ID: 25791825
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Diagnostic value of biopsy sampling in predicting histology in patients with diffuse malignant pleural mesothelioma.
    Chirieac LR; Hung YP; Foo WC; Hofer MD; VanderLaan PA; Richards WG; Sugarbaker DJ; Bueno R
    Cancer; 2019 Dec; 125(23):4164-4171. PubMed ID: 31390057
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Survival by Histologic Subtype of Malignant Pleural Mesothelioma and the Impact of Surgical Resection on Overall Survival.
    Verma V; Ahern CA; Berlind CG; Lindsay WD; Shabason J; Sharma S; Culligan MJ; Grover S; Friedberg JS; Simone CB
    Clin Lung Cancer; 2018 Nov; 19(6):e901-e912. PubMed ID: 30224273
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Highlighting the immunohistochemical differences of malignant mesothelioma subtypes via case presentations.
    Sejben A; Pancsa T; Tiszlavicz L; Furák J; Paróczai D; Zombori T
    Thorac Cancer; 2023 Apr; 14(10):857-863. PubMed ID: 36808895
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MDM2 and HIF1alpha expression levels in different histologic subtypes of malignant pleural mesothelioma: correlation with pathological and clinical data.
    Pasello G; Urso L; Mencoboni M; Grosso F; Ceresoli GL; Lunardi F; Vuljan SE; Bertorelle R; Sacchetto V; Ciminale V; Rea F; Favaretto A; Conte P; Calabrese F
    Oncotarget; 2015 Dec; 6(39):42053-66. PubMed ID: 26544728
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Malignant peritoneal mesothelioma: correlation between CT imaging features and histologic subtypes.
    Atre ID; Watane GV; Harisinghani MG
    Abdom Radiol (NY); 2021 Nov; 46(11):5105-5113. PubMed ID: 34342707
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combined MEK and PI3K/p110β Inhibition as a Novel Targeted Therapy for Malignant Mesothelioma Displaying Sarcomatoid Features.
    Marqués M; Tranchant R; Risa-Ebrí B; Suárez-Solís ML; Fernández LC; Carrillo-de-Santa-Pau E; Del Pozo N; Martínez de Villarreal J; Meiller C; Allory Y; Blum Y; Pirker C; Hegedus B; Barry ST; Carnero A; Berger W; Jean D; Real FX
    Cancer Res; 2020 Feb; 80(4):843-856. PubMed ID: 31911549
    [TBL] [Abstract][Full Text] [Related]  

  • 14. FGF2 and EGF induce epithelial-mesenchymal transition in malignant pleural mesothelioma cells via a MAPKinase/MMP1 signal.
    Schelch K; Wagner C; Hager S; Pirker C; Siess K; Lang E; Lin R; Kirschner MB; Mohr T; Brcic L; Marian B; Holzmann K; Grasl-Kraupp B; Krupitza G; Laszlo V; Klikovits T; Dome B; Hegedus B; Garay T; Reid G; van Zandwijk N; Klepetko W; Berger W; Grusch M; Hoda MA
    Carcinogenesis; 2018 Apr; 39(4):534-545. PubMed ID: 29635378
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pleomorphic epithelioid diffuse malignant pleural mesothelioma: a clinicopathological review and conceptual proposal to reclassify as biphasic or sarcomatoid mesothelioma.
    Kadota K; Suzuki K; Sima CS; Rusch VW; Adusumilli PS; Travis WD
    J Thorac Oncol; 2011 May; 6(5):896-904. PubMed ID: 21358344
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An Investigation of Cancer-Directed Surgery for Different Histologic Subtypes of Malignant Pleural Mesothelioma.
    Mansur A; Potter AL; Zurovec AJ; Nathamuni KV; Meyerhoff RR; Berry MF; Kang A; Jeffrey Yang CF
    Chest; 2023 May; 163(5):1292-1303. PubMed ID: 36574925
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pathology reporting of malignant pleural mesothelioma first diagnosis: A population-based approach.
    Ascoli V; Minelli G; Cozzi I; Romeo E; Carnovale Scalzo C; Ancona L; Forastiere F
    Pathol Res Pract; 2016 Oct; 212(10):886-892. PubMed ID: 27485167
    [TBL] [Abstract][Full Text] [Related]  

  • 18. AHNAK is highly expressed and plays a key role in cell migration and invasion in mesothelioma.
    Sudo H; Tsuji AB; Sugyo A; Abe M; Hino O; Saga T
    Int J Oncol; 2014 Feb; 44(2):530-8. PubMed ID: 24253341
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reproducibility of histological subtyping of malignant pleural mesothelioma.
    Brčić L; Jakopović M; Brčić I; Klarić V; Milošević M; Sepac A; Samaržija M; Seiwerth S
    Virchows Arch; 2014 Dec; 465(6):679-85. PubMed ID: 25300229
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact on survival of nuclear atypia in epithelioid malignant mesothelioma.
    Mlika M; Limam M; Benzarti A; Mezni F
    Adv Respir Med; 2019; 87(2):90-95. PubMed ID: 31038719
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.